Table of contents
June 2021 - Volume 80 - Suppl 1
- Scientific Abstracts
- Oral Presentations
- New perspectives on therapeutic immune tolerance
- Autoimmune diseases by abnormal T cell function
- What the rheumatologist needs to know to interpret studies in 2021
- Opening Plenary Abstract session
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases and Innate immunity in rheumatic diseases
- Of mice and man: insights into pathophysiology of rheumatoid arthritis and spondyloarthritis
- Molecular mechanisms in Connective Tissue Disease
- Clinical aspects of axial spondyloarthritis – science meets daily practice
- Vasculitis - I
- Vasculitis - II
- New toys in rheumatology: single cell RNA and epigenetic sequencing, the holy grail?
- Education
- The origins of pain in RMDs
- Infection-related rheumatic and orphan diseases
- Rheumatoid arthritis - comorbidity and clinical aspects - I
- Bone & Joints
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjögren’s and APS - treatment and SLE, Sjögren’s and APS - clinical aspects (other than treatment)
- Spondyloarthritis - treatment
- Diagnostics and imaging procedures
- Advances in Pediatric Rheumatology
- Progress in myositis and scleroderma research - I
- Rheumatoid arthritis - prognosis, predictors and outcome
- Oncorheumatology: the crossroads of cancer and musculoskeletal diseases
- Joint Session EULAR ESCMI and EANM (European Association of Nuclear Medicine) – State-of-the-art nuclear imaging in RMDs
- Comorbidities in gout and hyperuricaemia
- Immune events with checkpoint inhibitors
- The aftermath of metabolic imbalance in OA
- Emerging molecular targets in OA
- Origin and role of myeloid cells during homeostasis and inflammation
- Crystal diseases
- Rheumatoid arthritis - comorbidity and clinical aspects - II
- Unrevealing the impact of PsA and comorbidity prevention
- Psoriatic arthritis - treatment
- Epidemiology and public health
- Systemic sclerosis, myositis - etiology, pathogenesis and animal models
- Imaging in axial spondyloarthritis – what is new?
- Progress in myositis and scleroderma research - II
- New Developments in COVID-Research
- SLE, Sjörgen's and APS - Clinical Aspects
- Difficult to treat RA: definitions and mechanisms
- Quantitative imaging
- Let’s consider Biologic Immunogenicity
- Controversies on phenotypes in PsA
- Pharmacology and Microbiota
- What can we learn from the tissue
- EULAR Projects in musculoskeletal imaging
- What's new: Latest advances in treatment and care in vasculitis and fibromyalgia
- Stress, inflammation & autoimmunity
- Hyperinflammation and Covid19
- Metabolic pathways during the regulation of inflammation and immunity
- Let's work. Together.
- Deconditioning in rheumatic disease, time to recognise and tackle it
- EFIS session: Emerging concepts how B cells drive systemic autoimmunity: from bench to clinic
- Late breaking abstracts
- Poster Tours
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Epidemiology and treatment of pain in RMDs
- Epidemiology: Big Questions - Big studies
- Imaging in axial spondyloarthritis
- Molecular and structural changes of bone turnover during inflammatory disease
- New Developments in COVID research
- Pediatric Rheumatology – Basic and translational science
- Pediatric Rheumatology - Clinical
- Rheumatoid arthritis - non biologic treatment and small molecules - PART 1
- Rheumatoid arthritis - prognosis, predictors and outcome
- SLE, Sjögren’s and APS - clinical
- Translating vasculitis
- Central pain and other extra-articular associations to KOA
- Crystal arthritis
- Fine-tuning strategies (beyond treatments) to reduce the impact of PsA
- Metabolic bone disease / Osteoporosis
- Molecular profiles in connective tissue disease outcome
- PROMs and markers
- PsA treatment: what is new?
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid Arthritis - comorbidity and clinical aspects - Part 1
- Rheumatoid arthritis - non biologic treatment and small molecules - PART 2
- Spondyloarthritis - treatment
- Clinical aspects of spondyloarthritis
- Clinical vasculitis
- Diagnostics and imaging procedures
- New drugs and therapies
- Oncorheumatology
- Public Health, Health Services and Health Economics
- Rheumatoid Arthritis - comorbidity and clinical aspects - Part 2
- Scleroderma, myositis and related syndromes
- Systemic sclerosis, myositis - etiology, pathogenesis and animal models
- Vasculitis - Large vessel vasculitis
- POSTERS only
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Osteo arthritis, aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Spondyloarthritis - aetiology, pathogenesis and animal models
- SLE, Sjögren’s and APS - aetiology, pathogenesis and animal models
- Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
- Basic and translational pain science
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS - clinical aspects (other than treatment)
- Vasculitis – large vessel vasculitis
- Vasculitis – small vessel vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis – treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis – treatment
- Psoriatic arthritis - clinical aspects (other than treatment)
- Osteoarthritis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- COVID-19
- Spine, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Education
- Educational cases
- Publication Only
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Osteo arthritis, aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Spondyloarthritis - aetiology, pathogenesis and animal models
- SLE, Sjögren’s and APS - aetiology, pathogenesis and animal models
- Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
- Vasculitis - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS - clinical aspects (other than treatment)
- Vasculitis – small vessel vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis – treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis – treatment
- Psoriatic arthritis - clinical aspects (other than treatment)
- Osteoarthritis
- Osteoporosis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- COVID-19
- Pain in rheumatic diseases, including fibromyalgia
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Education
- Educational cases
- Oral Presentations
- Health Professionals in Rheumatology Abstracts
- Oral Presentations
- Like a gearwheel: HPR’s research, education, and practice
- Rheumatoid arthritis - comorbidity and clinical aspects - I
- HPR Abstract Session (I)
- Monitoring and restoring health: Should we have a core set for multidisciplinary care in rheumatology
- HPR Abstract Session (II)
- Context matters: Placebo and nocebo effects for pain management
- Myths and taboos around relationships: strategies for a sexy life
- [Joint session HPR/ PARE/ ARP] Mastering Self-management: State of art in a New Era
- Poster Tours
- POSTERS only
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Service developments, innovation and economics in healthcare
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- Publication Only
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Service developments, innovation and economics in healthcare
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- Oral Presentations
- People with Arthritis and Rheumatism in Europe Abstracts
- Oral Presentations
- Opening Plenary Abstract session
- Challenges for Patients and Patients’ Organisations in Times of the Pandemic
- Challenges for working people with RMDs in pandemic times
- Improving collaborative research and patients’ participation in health decision-making
- PARE Abstract session
- Myths and taboos around relationships: strategies for a sexy life
- Let’s work. Together.
- Members and Volunteers – Unknown beings? How to explore their interests, establish contacts and support
- Poster Tours
- POSTERS only
- Publication Only
- Oral Presentations